晚期结肠癌的第三线治疗对长期生存有好处:一个病例报告

Ju Su1, Yuqing Kuang1, Yiwen Wu2

  • 1Department of Oncology, People's Hospital of Xiangxi Autonomous Prefecture/The First Affiliated Hospital of Jishou University, Jishou, China.

Frontiers in immunology
|September 29, 2025
PubMed
概括

第三线免疫疗法与向治疗相结合,可为转移性结直肠癌 (mCRC) 患者提供长期无进展的生存期. 这项案例研究突出了弗鲁昆丁尼布和辛蒂利马布作为对熟练不匹配修复 (pMMR) mCRC.的有希望的治疗方法.